Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 2Phase 1/2 2Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Gliosarcoma 1Glioblastoma 1

Interventions

Temozolomide 11Lomustine 6Radiotherapy 4Magnetic Resonance Spectroscopy 3Etoposide 3Carboplatin 3Bevacizumab 3vocimagene amiretrorepvec 2Vincristine 2Radiation 2Gefitinib 2veliparib 1trofosfamide 1trametinib 1tozuleristide 1tinostamustine 1regorafenib 1omburtamab I-131 1entrectinib 1dabrafenib 1cobimetinib 1carbon-11 acetate 1capmatinib 1antisecretory factor 1alectinib 1Vorinostat 1Vemurafenib 1Thiotepa 1Sunitinib 1Standard of Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × veliparib × CNS × Clear all
NCT02152982 2026-04-28

Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
447 enrolled 20 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡